Main Article Content
Bacteriophage, Probiotics, Human microbiota, Lytic phage, Phage supplementation
Human gastrointestinal tract is colonized by bacteria that constitute the interstinal microbiota. Changes in the microbiota may lead to several chronic disorders. Bacteriophages are viruses that specifically target bacteria. Several food components contain bacteriophages and probiotics. Bacteriophages have a great specificity for harmful bacteria, helping the growth of good bacteria. Because of their qualities, bacteriophages are considered beneficial component of probiotics that target the pathogenic bacteria and support the natural human microbiota.
2. Fernández L, Gutiérrez D, Rodríguez A, García P. Application of bacteriophages in the agro-food sector: A long way toward approval. Front Cell Infect Microbiol 2018; 8: 296.
3. Gindin M, Febvre HP, Rao S, Wallace TC, Weir TL. Bacteriophage for Gastrointestinal Health (PHAGE) Study: Evaluating the safety and tolerability of supplemental bacteriophage consumption. J Am Coll Nutr 2019; 38(1): 68-75.
4. Watkins RR, Bonomo RA. Overview: Global and local impact of antibiotic resistance. Infect Dis Clin North Am 2016; 30(2): 313-22.
5. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. In: Mayo Clinic Proceedings; Elsevier, 2014.
6. Downey M. Phages improve intestinal and immune health. 2018. Available from: https://www.lifeextension.com/magazine/2018/7/kill-harmful-bacteria-to-improve-intestinal-health.
7. Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21(1): 102-11.
8. Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M. Bacteriophage therapy: A regulatory perspective. J Antimicrob Chemother 2016; 71(8): 2071-4.
9. Sulakvelidze A. Bacteriophage-based probiotic preparation for managing Shigella infections. 2015. Available from: https://www.sbir.gov/sbirsearch/detail/377940.
10. Sulakvelidze A. Bacteriophage: A new journal for the most ubiquitous organisms on Earth. Bacteriophage 2011; 1(1): 1-2.
11. Aleshkin AV, Volozhantsev NV, Svetoch EA, et al. Bacteriophages as probiotics: Phage-based probiotic dietary supplement in prophylaxis against foodborne infections. Infectious Diseases 2016; 14(2): 31-40.
12. Francino M. Antibiotics and the human gut microbiome: Dysbioses and accumulation of resistances. Front Microbiol 2016; 6: 1543.
13. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. Sci Rep 2016; 6: 39399.
14. Sherry CL, Kim SS, Dilger RN, et al. Sickness behavior induced by endotoxin can be mitigated by the dietary soluble fiber, pectin, through up-regulation of IL-4 and Th2 polarization. Brain Behav Immun 2010; 24(4): 631-40.
15. Muir AB, Benitez AJ, Dods K, Spergel JM, Fillon SA. Microbiome and its impact on gastrointestinal atopy. Allergy 2016; 71(9): 1256-63.
16. Samtlebe M, Ergin F, Wagner N, et al. Carrier systems for bacteriophages to supplement food systems: Encapsulation and controlled release to modulate the human gut microbiota. LWT-Food Science and Technology 2016; 68: 334-40.
17. Letarov A, Kulikov E. The bacteriophages in human- and animal body-associated microbial communities. J Appl Microbiol 2009; 107(1): 1-13.
18. Middelboe M, Holmfeldt K, Riemann L, Nybroe O, Haaber J. Bacteriophages drive strain diversification in a marine Flavobacterium: Implications for phage resistance and physiological properties. Environ Microbiol 2009; 11(8): 1971-82.
19. Ventura M, Turroni F, Lima-Mendez G, et al. Comparative analyses of prophage-like elements present in bifidobacterial genomes. Appl Environ Microbiol 2009; 75(21): 6929-36.
20. Ventura M, Sozzi T, Turroni F, Matteuzzi D, van Sinderen D. The impact of bacteriophages on probiotic bacteria and gut microbiota diversity. Genes Nutr 2011; 6(3): 205-7.
21. Ventura M, Turroni F, Canchaya C, Vaughan EE, O'Toole PW, van Sinderen D. Microbial diversity in the human intestine and novel insights from metagenomics. Front Biosci (Landmark Ed) 2009; 14: 3214-21.
22. Ventura M, O'Flaherty S, Claesson MJ, et al. Genome-scale analyses of health-promoting bacteria: Probiogenomics. Nat Rev Microbiol 2009; 7(1): 61-71.
23. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4(3): e4944.
24. Jończyk-Matysiak E, Weber-Dąbrowska B, Owczarek B, et al. Phage-phagocyte interactions and their implications for phage application as therapeutics. Viruses 2017; 9(6): 150.
25. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011; 1(2): 111-4.
26. Aleshkin AV, Volozhantsev N, Svetoch EA, Afanasiev S. Bacteriophages as probiotics and decontaminating agents for food products. Asia-Pacific Journal of Life Sciences 2013; 7(1): 91.
27. European Food Safety Authority (EFSA). Scientific opinion on the evaluation of the safety and efficacy of Listex™ P100 for the removal of Listeria monocytogenes surface contamination of raw fish. EFSA Journal 2012; 10(3): 2615.
28. Klumpp J, Dorscht J, Lurz R, et al. The terminally redundant, nonpermuted genome of Listeria bacteriophage A511: A model for the SPO1-like myoviruses of gram-positive bacteria. J Bacteriol 2008; 190(17): 5753-65.
29. Boratyński J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska M, Poźniak G, Górski A. Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 2004; 9(2): 253-9.
30. Carlton RM, Noordman WH, Biswas B, de Meester ED, Loessner MJ. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 2005; 43(3): 301-12.